Taclonex
Loading...Taclonex Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
There is currently no warning information available for this product. We apologize for any inconvenience.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
Taclonex® Ointment is indicated for the topical treatment of psoriasis vulgaris in adults 18 years of age and above for up to 4 weeks. The maximum weekly dose should not exceed 100 g. Treatment of more than 30% body surface area is not recommended.
Taclonex® Ointment should not be applied to the face, axillae or groin.
History
There is currently no drug history available for this drug.
Other Information
Taclonex® Ointment contains calcipotriene hydrate and betamethasone dipropionate.
It is intended for topical use.
Calcipotriene hydrate is a synthetic vitamin D3 analogue.
Chemically, calcipotriene hydrate is (5Z,7E,22E,24S)-24-cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1(α),3(β),24-triol,hydrate, with the empirical formula C27H40O3,H2O, a molecular weight of 430.6, and the following structural formula:
Calcipotriene hydrate is a white to almost white crystalline compound.
Betamethasone dipropionate is a synthetic corticosteroid.
Betamethasone dipropionate has the chemical name 9-fluoro-11(β),17,21-trihydroxy-16(β)-methylpregna-1,4-diene-3,20-dione17,21-dipropionate, with the empirical formula C28H37FO7, a molecular weight of 504.6, and the following structural formula:
Betamethasone dipropionate is a white to almost white odorless powder.
Each gram of Taclonex® Ointment contains 52.18 mcg of calcipotriene hydrate (equivalent to 50 mcg of calcipotriene) and 0.643 mg of betamethasone dipropionate (equivalent to 0.5 mg of betamethasone) in an ointment base of mineral oil, PPG-15 stearyl ether, dl-alpha tocopherol and white petrolatum.
Sources
Taclonex Manufacturers
-
Warner Chilcott (Us), Llc
![Taclonex (Calcipotriene And Betamethasone Dipropionate) Ointment [Warner Chilcott (Us), Llc]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Taclonex | Warner Chilcott (us), Llc
Apply an adequate layer of Taclonex® Ointment to the affected area(s) once daily for up to 4 weeks. Taclonex® Ointment should be rubbed in gently and completely. The maximum weekly dose should not exceed 100 g. Treatment of more than 30% body surface area is not recommended. Taclonex® Ointment should not be applied to the face, axillae or groin.
-
Physicians Total Care, Inc.
Taclonex | Physicians Total Care, Inc.
2.1 Usual Dosage and AdministrationApply an adequate layer of Taclonex® Ointment to the affected area(s) once daily for up to 4 weeks. The maximum weekly dose should not exceed 100 g. Treatment of more than 30% body surface area is not recommended. Taclonex® Ointment should be rubbed in gently and completely. Patients should wash their hands after applying Taclonex® Ointment.
Taclonex® Ointment is not for oral, ophthalmic, or intravaginal use.
-
Leo Pharma Inc.
Taclonex | Leo Pharma Inc.
Apply an adequate layer of Taclonex® Ointment to the affected area(s) once daily for up to 4 weeks. Taclonex® Ointment should be rubbed in gently and completely. Patients should wash their hands after applying Taclonex®Ointment. Therapy should be discontinued when control is achieved.
Patients 18 years and older should not use more than 100 g per week and patients 12 to 17 years should not use more than 60 g per week. Treatment of more than 30% body surface area is not recommended.
Taclonex® Ointment should not be used with occlusive dressings unless directed by a physician. Avoid use on the face, groin, or axillae, or if skin atrophy is present at the treatment site. Taclonex® Ointment is not for oral, ophthalmic, or intravaginal use.
-
Leo Pharma Inc.
Taclonex | Leo Pharma Inc.
Instruct patients to shake bottle prior to using Taclonex® Topical Suspension and to wash their hands after applying the product.
Apply Taclonex® Topical Suspension to affected areas once daily for up to 8 weeks. Therapy should be discontinued when control is achieved.
Patients 18 years and older should not use more than 100 g per week and patients 12 to 17 years should not use more than 60 g per week.
Taclonex® Topical Suspension should not be used with occlusive dressings unless directed by a physician. Taclonex® Topical Suspension is not for oral, ophthalmic, or intravaginal use. Avoid use on the face, groin, or axillae, or if skin atrophy is present at the treatment site.
![Taclonex (Calcipotriene And Betamethasone Dipropionate) Ointment [Physicians Total Care, Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4fe9ed32-0843-4a05-a5f2-d2e6325bbb9a&name=5680.jpg)
![Taclonex (Calcipotriene And Betamethasone Dipropionate) Ointment [Leo Pharma Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ef43ba2d-20ce-4415-b5c2-e486b836812e&name=tac-ointment-100g.jpg)
![Taclonex (Calcipotriene And Betamethasone Dipropionate) Suspension [Leo Pharma Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=757c914f-dd8d-43cc-a973-212d591af4af&name=120g-carton.jpg)
Login To Your Free Account